Get the latest news and updates
Cancer genomic profiling can identify germline and medically actionable mutation(s) in cancer predisposition genes. This can present a complex problem for diagnostics labs because of broader implications regarding the patient’s overall health risk, risk of future cancers, and implications for the patient’s family. This panel discussion will focus on how diagnostics labs are addressing this complexity.
Ellen T. Matloff founded the Yale Cancer Genetic Counseling program, served as its director and a faculty member at Yale School of Medicine for 18 years, and was a lead plaintiff in the SCOTUS BRCA gene patent case of 2013. She works closely with patient advocates in the areas of genetic counseling and testing, and direct-to-consumer (DTC) genetic testing, and is an expert in responsible return of genetic test results and scalable updating for population studies, health care systems, and precision medicine partners. Matloff serves as the Forbes.com contributor on genetic counseling, genetic testing, and digital health.
In her current role, Suzanne focuses on commercial strategy and growth for Tempus developing and executing partnerships with organizations to improve healthcare value and outcomes by leveraging molecular and clinical data. Value creation for commercial payers, benefit managers and group purchasing organizations is where she focuses. Dr. Belinson is especially interested in applications of data to power solutions for the transition to and management of value based care. Prior to Tempus, Dr. Belinson served as Executive Director, Clinical Markets, at the Blue Cross Blue Shield Association where she led the sales and market development as well as day to day operations of Evidence Street. Dr. Belinson received her bachelor’s degree from Cleveland State University, a Masters in Public Health from the University of Pittsburgh, and a PhD in Epidemiology from the University of North Carolina at Chapel Hill.
Ms. Perettie is passionate about improving the care of cancer patients and brings more than two decades of scientific and commercial experience with global biopharmaceutical organizations. Prior to joining Foundation Medicine, Ms. Perettie served as Senior Vice President in global oncology product strategy for Roche’s Oncology unit. Ms. Perettie began her tenure at Genentech as a program team leader for bevacizumab, and she led several successful therapy launches in the U.S. and abroad for Roche and Genentech across the oncology portfolio, including in lung cancer, breast cancer and hematology. In 2012, Ms. Perettie took a hiatus from Genentech to join Sarah Cannon Research Institute as President, Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. Before joining Genentech, Ms. Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corporation. Her pharmaceutical experience began as a research scientist associate director role at Chiron Corporation.